KRW 11870.0
(-2.63%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 27.25 Billion KRW | -44.7% |
2022 | 49.29 Billion KRW | 352.39% |
2021 | 10.89 Billion KRW | -76.63% |
2020 | 46.62 Billion KRW | 119.72% |
2019 | 21.22 Billion KRW | 4.59% |
2018 | 20.28 Billion KRW | -8.86% |
2017 | 22.26 Billion KRW | -25.31% |
2016 | 29.8 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 9.4 Billion KRW | -78.13% |
2024 Q1 | 43.01 Billion KRW | 57.83% |
2023 Q2 | 56.48 Billion KRW | -38.75% |
2023 Q4 | 27.25 Billion KRW | -43.92% |
2023 Q3 | 48.6 Billion KRW | -13.96% |
2023 Q1 | 92.21 Billion KRW | 87.09% |
2023 FY | 27.25 Billion KRW | -44.7% |
2022 Q4 | 49.29 Billion KRW | 124.57% |
2022 Q3 | 21.94 Billion KRW | -5.88% |
2022 Q2 | 23.32 Billion KRW | -42.19% |
2022 Q1 | 40.33 Billion KRW | 331.71% |
2021 Q4 | 9.34 Billion KRW | -23.43% |
2021 Q3 | 12.2 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
InBody Co.,Ltd | 24.62 Billion KRW | -10.701% |
Curexo Inc. | 6.94 Billion KRW | -292.679% |
Seegene, Inc. | 221.05 Billion KRW | 87.67% |
i-SENS, Inc. | 195.32 Billion KRW | 86.046% |
Ray Co., Ltd. | 128.35 Billion KRW | 78.765% |
Gencurix Inc. | 21.49 Billion KRW | -26.781% |
Sugentech Inc. | 20.73 Billion KRW | -31.467% |
L&C Bio Co., Ltd | 105.37 Billion KRW | 74.134% |